
ã¯ã¯ãã³ã®10ã®åé¡ç¹ - ãããŠ10ã®è§£æ±ºç
å èšäºã¯ãã¡ããã/Click here to read the original article.
ãã¯ã¯ãã³ã®ç¡è¬¬æ§ãšãã硬çŽããç¬æçãªä¿¡å¿µã«ãšããããŠããã人ãç¥ã£ãŠããŸããïŒã¯ã¬ã€ãã³ã»Jã»ãã€ã«ãŒå士ã¯ããã¯ã¯ãã³ã®åé¡ç¹ãã10åæãããã®è§£æ±ºçã10åæããŠããã
ã¯ã¯ãã³ã«å¯Ÿããç¡æ¹å€çã§ç²ç®çãªä¿¡ä»°ã¯ãçŸä»£å»åŠã®åè¶ããèãªãçã§ãããããã¯ãå¥å šãªç§åŠççè«ãçµéšã«åºã¥ããèšåºçæèšãšãããããããããæºå®æçã§ç¬æçãªä¿¡å¿µã®ç£ç©ãªã®ã§ããã
ã¯ã¯ãã³ã¯äœäžçŽãåã«å°å ¥ãããŠä»¥æ¥ãè«äºãå·»ãèµ·ãããŠãããããæè¿ã«ãªã£ãŠãããããå»åŠçã®æš©åšã®éã§ãã¯ã¯ãã³ã¯ãå®å šã§å¹æçãã§ãããåçç¡çšã§ãããšå šäŒäžèŽã§èŠãªãããªããã°ãªããªããšããã峿 Œã«åŒ·å¶ãããæ£çµ±æŽŸã®ä¿¡å¿µã確ç«ãããã®ã§ããã
ããã«æè¿ã«ãªã£ãŠããã®æçŸ©ã«çåãåããè ãç°ç«¯è ãã€ãŸã "åã¯ã¯ãã³è«è "ãšããŠäžå·ããã¬ããã«ã貌ãããã«ãªã£ãã
å®éãMerriam-Webster Dictionaryã«ããã°ãçŸåšã§ã¯äžè¬çãªãã®åŒç§°ã䜿ãããããã«ãªã£ãã®ã¯ã2001幎ã®ããšã§ããã
宿çãªä¿¡ä»°ã¯ç€ŸäŒã«ãšã£ãŠéåžžã«å€§ããªå¯èœæ§ãç§ããŠãããããããç§åŠãšããŠèª€ã£ãŠè¡šçŸãããå Žåããã®å®çžŸã¯æ²æšã§èŽåœçãªãã®ãšãªãã
ãå®å šã§å¹æçããšããã®ã¯ç§åŠçãªç¥èªã§ããªããã°ãåºåã¹ããŒã¬ã³ã§ããªãããã¢ã³ãã»ã¯ã¯ãã³è«è ãã¯äººã®ã«ããŽãªãŒã§ã¯ãªããç°ç«¯ã®åçºã§ãããã¯ã¯ãã³æ¹å€è ãç°ç«¯ã§ããããã«ãã¯ã¯ãã³ã®é«å§ãäžçã®ãã©ãŒã·ã¹ã圌ãèªèº«ã®èšèã§ "ç§åŠã代衚ãã "人ã ã¯çä¿¡è ãªã®ã ã
ãããæ¬åœã«ç§åŠã ãšæããŸããïŒã¬ãªã¬ãªããŒã³ã¡ã«ã¯ã€ã¹ããã®ä»äœäººãã¯ããæããªããããããªãã
ç±³åœã®COVID-19æä»£ãçããèª å®ãªäººãªã誰ã§ããç±³åœä¿å¥çŠç¥çïŒHHSïŒãšãã®é·ã "ã¢ã«ãã¡ãããã¹ãŒã "ã®ãããªæ©é¢ïŒçŸç 察çäºé²ã»ã³ã¿ãŒïŒCDCïŒãåœç«ã¢ã¬ã«ã®ãŒã»ææçç ç©¶æãæããåœç«è¡çç ç©¶æïŒNIHïŒãçç©è£œå€è©äŸ¡ç ç©¶ã»ã³ã¿ãŒãæããç±³åœé£åå»è¬åå±ïŒFDAïŒãªã©ïŒãããå®å šã§å¹æçãªå»è¬åããæšé²ããç¹°ãè¿ããŠããããšãèªããã ããã COVID-19ã¯ã¯ãã³ã«é¢ãããå®å šã§å¹æçããšãããã³ãã©ã¯ãå ¬è¡ã®ææã®æä»£ãéããŠå®£äŒãããç¹°ãè¿ãããã
æ£çŽãªäººãªã誰ã§ããäž»æµã¡ãã£ã¢ãç±å¿ã«ãå®å šã§å¹æçããšãããã³ãã©ãç¹°ãè¿ããå¢å¹ ãããææãç œã£ãããšãèªããã ããããã®äžæ¹ã§ãåããã°ãã«çåãåããè ãå·é ·ã«æ»æãã"åã¯ã¯ãã³è«è "ãæã«ã¯ "殺人è "ãšããã¬ããã«ã貌ã£ãã
ãããã®åŒ·åãªå£äœãã¯ã¯ãã³è£œé æ¥è ãšçµãã§ãã巚倧ãªééçã€ã³ã»ã³ãã£ãããã®ä»ã®çµ¡ã¿åãããããŠäœå ãã«ãã®éã絡ãã§ããããšã«ã€ããŠã¯ãã»ãšãã©èšåãããªãã£ããããããããšããªãã£ãã
宿çãã°ãããšãããæ¥µéç¶æ ã®ããšã§åŒ·åãªåã«ãã£ãŠå·æã«æ€ãã€ãããããã°ãããæãåºãã®ã¯é£ããã
ã¯ã¯ãã³ã®ç¡è¬¬æ§ïŒãã³ã ãããïŒã«å¯Ÿãã硬çŽããç¬æçãªä¿¡å¿µã«ãšããããŠãã人ã ãç¥ã£ãŠãããããããªãèªè ã«ãç§ã¯æ¬¡ã®10æãæäŸããã
ã¯ã¯ãã³ã®ãã°ããåèããããšãã§ããªããããªå人ãå®¶æãååãç¹ã«çŸåšã®ã¯ã¯ãã³ã¹ã±ãžã¥ãŒã«ãç¡æ¹å€ã«èŠãŠãã人ãã¡ãšå ±æããŠãã ããã
以äžã®10ã®æç« ã1ã€ãã€æ³šææ·±ãèªãã§ããããèªåããŠã»ããã
ããåã ãšããããç§ã¯äœãæ ¹æ ã«åã ãšæããïŒãããŠæ¬¡ã®æã«ç§»ããåãããšãããã(äžã«ã¯è€éãªæç« ãããããç¥çãªçŽ äººãªããã¹ãŠçè§£ã§ãããšç¢ºä¿¡ããŠãã)ã
10åã®æç« ããã¹ãŠæžãçµããããåéã«èªåããããå§ããïŒ
圌ãã¯ãç±³åœã®ãã¹ãŠã®åäŸã18æ³ãŸã§ã«20çš®é¡ä»¥äžã®ã¯ã¯ãã³ãåããã¹ãã ãšæ¬åœã«ä¿¡ããŠããã®ã ãããïŒ
ã¯ã¯ãã³ã¯çŸ©ååãããã¹ããªã®ãïŒ
æè²ãããèªç±ãªç€ŸäŒãšããŠãç§ãã¡ã¯å ¬åŒã®æšå¥šã¯ã¯ãã³ãäœç³»çã«èŠçŽãããã°ãã¡ããã®æº¢ããã°ããã®è¬ç®±ãšåãããã«ãæ¬åœã«å¿ èŠãªæå°éã®ã¯ã¯ãã³ã«æžããã¹ãã§ã¯ãªãã®ãïŒ
èªåã®èº«äœã«å¯Ÿããæ£è ã®èªåŸæ§ãåã³äž»åŒµãã¹ãã§ã¯ãªãã ãããïŒ
ã¯ã¯ãã³ã®åé¡ç¹ã10è¡ã§èª¬æãããïŒ
ãæçç©è³ªããšåæ§ããã¯ã¯ãã³ãã¯å€§èŠæš¡ã§å€æ§ãªå»è¬åã®ã¯ã©ã¹ã§ãããä»ã®å€§èŠæš¡ãªå»è¬åã®ã¯ã©ã¹ãšåæ§ãã¯ã©ã¹å ã®ç°ãªã補åãç°ãªãã¡ã«ããºã ã§äœçšãããããã®ã¯éåžžã«å¹æçã§ãããããããã®ã¯å¹æããªãããããã®ã¯é©åãªãããžã®äœ¿çšã«å¯ŸããŠåççã«å®å šã§ãããããããã®ã¯å¯äœçšãæ¯æ§ã䌎ãããããã£ãŠãã¯ã¯ãã³ãå«ãå€§èŠæš¡ãªå»è¬åã®ã¯ã©ã¹ãäžæŠã«ãå®å šã§å¹æçãã§ãããšä»®å®ããããšã¯ããã€ãŒãã§éè«ççã§ããã誀ãã§ãããå±éºã§ããã
ã¯ã¯ãã³ã®æ¯æ§ã®å šå®¹ã¯æªç¢ºå®ã§ããããå€ãã®ã¯ã¯ãã³ãã以äžã®ãããªè€æ°ã®ç æ ççåŠçã¡ã«ããºã ãéããŠãæ£è ã«åŒ·ãæ¯æ§ã瀺ããæ»ã«è³ãããšããããããšã蚌æãããŠããããšã¯æŽå²çäºå®ã§ããïŒ
ã¯ã¯ãã³ã®çŽæ¥æ±æïŒã«ãã¿ãŒäºä»¶ãªã©ïŒ
ã¯ã¯ãã³ã«å¯Ÿããäºæãã¬ç çå ç«åå¿ã«ããçŸç ïŒäŸïŒè±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ã«ããã®ã©ã³ã»ãã¬ãŒçå矀ïŒ
ã¯ã¯ãã³èªäœã«ãã£ãŠåŒãèµ·ãããããã¯ã¯ãã³ãäºé²ããããã«èšèšãããç æ°ã®æå³ããªãææãäŒæïŒäŸïŒçŸè¡ã®çµå£ããªãªã¯ã¯ãã³ïŒåå äžæãŸãã¯äžç¢ºå®ãªã¯ã¯ãã³æ¯æ§ïŒäŸïŒãã¿ãŠã€ã«ã¹ã¯ã¯ãã³ã«ããè žæ»è»¢ããžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³COVID-19ã¯ã¯ãã³ã«ããèŽæ»çè¡æ ïŒ
3. å®éãã¯ã¯ãã³ã®æ¯æ§ã¯ããç¥ãããŠããã1986幎ã«å¶å®ãããé£éŠæ³ãå°å
ã¯ã¯ãã³å·å®³æ³ïŒNCVIAïŒãïŒåè¡åœæ³å
žç¬¬42線第300aa-1æ¡ãã第300aa-34æ¡ïŒã¯ãã¯ã¯ãã³ããäžå¯é¿çã«å®å
šã§ãªãã補åã§ãããšããæ³çååã«åºã¥ããã¯ã¯ãã³è£œé æ¥è
ã®è£œé ç©è²¬ä»»ãæç¢ºã«å
é€ããããã«å¶å®ãããã
4. 1986幎ã«NCVIAæ³ãå¶å®ãããã¯ã¯ãã³è£œé æ¥è
ã®è²¬ä»»ãå
é€ãããŠä»¥æ¥ãåžå Žã«åºåãã¯ã¯ãã³ã®æ°ã¯é£èºçã«å¢å ãããŸãCDCã®ã¯ã¯ãã³ã¹ã±ãžã¥ãŒã«ã«è¿œå ãããã¯ã¯ãã³ã®æ°ãå¢å ããCDCã®å°å
ã»ææ¥æã¹ã±ãžã¥ãŒã«ã®ã¯ã¯ãã³æ°ã¯1986幎ã®7çš®é¡ãã2023幎ã«ã¯21çš®é¡ã«å¢å ããŸããã
5. 5.2023幎CDCå°å
ã»ææ¥æäºé²æ¥çš®ã¹ã±ãžã¥ãŒã«ã«ãã21ã®ã¯ã¯ãã³ã®ãã¡ãçã®éå£å
ç«ãæäŸã§ããã®ã¯ããå°æ°ïŒéº»ç¹ããããµãããã颚ç¹ãæ°ŽçãHiBãªã©ïŒã§ããããã®äºå®ã¯ãã¹ã±ãžã¥ãŒã«ã«ããã¯ã¯ãã³ã®ããªãã®å€§å€æ°ãå ããä»ã®ã¯ã¯ãã³ã矩åä»ããäžè¬çãªéå£ããŒã¹ã®è°è«ãåŠå®ãããã®ã§ããã
6. è£œè¬æ¥çã¯ãä»ã®å£äœãžã®è³éæäŸãéããŠãæ³åãçµ¶ããã»ã©ã®ã¡ãã£ã¢ã³ã³ãããŒã«ãå¶åºŠç圱é¿åãèŠå¶ã®ææ¡ã確ç«ããŠããïŒ
ã¯ã·ã³ãã³D.C.æå€§ã®æ¥çãããŒã
ãã¬ãåºåæ¥ç第2äœ
HHSã® "ã¢ã«ãã¡ãããã¹ãŒã "ãšåŒã°ããé«çŽå®åã®äž»ãªå人åå ¥æºã§ããããã®å€ãã¯å»è¬åã®ç¹èš±æš©ããã€ã€ãªãã£æš©ãä¿æããŠããã
圱é¿åã®ããå»åž«å£äœïŒç±³åœå°å ç§åŠäŒãèåãªå»åŠéèªãªã©ïŒã®äž»èŠãªè³éæºã
鿥å»ãžã®æ¯æãã«åºã¥ãã€ã³ã»ã³ãã£ãä»äžã«é¢äžããŠããã鿥å»ã¯æ£è ããã«ã«ãããã¯ã¯ãã³æ¥çš®çã®é«ãã«ãããé »ç¹ã«ééçããŒãã¹ãåãåã£ãŠããã
7.ãCOVID-19 mRNAã¯ã¯ãã³ãéçºãããäžè¬ã«æäžãããïŒ
åžè²©ãããŠããä»ã®ã©ã®ã¯ã¯ãã³ããããã¯ããã«è¿ éã§ãã¯ããã«å°ãªãæ€æ»ã§ã
ç·æ¥äœ¿çšèš±å¯ã®äžã
ãããŸã§åæ¥çã«äœ¿çšãããããšã®ãªãæè¡çãã©ãããã©ãŒã ãå©çšããåŸæ¥ã®ã¯ã¯ãã³ãããã¯ããã«é«ã確çã§ãã¯ã¯ãã³ã«é¢é£ããæ»äº¡äŸãéç¯€ãªæå®³äºè±¡ãå ±åãããŠããã«ããããããã
ãŸããä»ã®è€æ°ã®å é²åœã§ã¯å°å çšã¯ã¯ãã³åžå Žããæé€ãããŠããã«ãããããããCOVID-19 mRNAã¯ã¯ãã³ã¯ãäžè¬ãžã®å°å ¥ããããã2幎ããŸãã§ããã§ã«CDCã®å°å ã»ææ¥æäºé²æ¥çš®ã¹ã±ãžã¥ãŒã«ã«æ²èŒãããŠããã
8. 7æ7æ¥ã®æç¹ã§CDCèªèº«ã®ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã«å ±åããã35,000件以äžã®COVID-19ã¯ã¯ãã³é¢é£æ»äº¡äŸãš1,500,000件以äžã®COVID-19ã¯ã¯ãã³é¢é£æå®³äºè±¡ã®å ±åã«ã€ããŠãCDCïŒãããã¯HHSã®ã©ã®æ©é¢ãïŒã«ããäœç³»çãªå
¬è¡šã¯ãªãã ãŸããCDCãCDCã®å°å
ã»ææ¥æäºé²æ¥çš®ã¹ã±ãžã¥ãŒã«ã«æ²èŒãããªã©ããããã®ã¯ã¯ãã³ã®äœ¿çšãåŒ·ãæšé²ãç¶ããŠããã«ãããããããEudravigilanceïŒVAERSã«çžåœããæ¬§å·é£åïŒã«å ±åãããCOVID-19ã¯ã¯ãã³é¢é£ã®æ»äº¡ãæå®³äºè±¡ã®å¯Ÿå¿ããæ°ã«ã€ããŠãåæ§ã§ããã
9. æ°èŠã®COVID-19 mRNA補åããã¯ã¯ãã³ããšè¡šç€ºããããšã«ãã£ãŠããã¯ã¯ãã³ããšããçšèªã®å®çŸ©ãéåžžã«æ¡å€§ãããç
æ°ã«å¯Ÿããå
ç«åå¿ãèªå°ããæ¬è³ªçã«ããããè¬ããã¯ã¯ãã³ããšåŒã°ããããã«ãªããããã«ãã£ãŠè£œè¬äŒç€Ÿã¯NCVIAã«åºã¥ã責任ãã以åã«ã¯æ³åãã§ããªãã£ãã»ã©å
ããããšã«ãªã£ãã
10. ã¯ã¯ãã³æ¥çš®ã®çŸ©ååã«ãã£ãŠãåžæ°ã¯å»çè¡çºãåããããšãäœåãªããããïŒ
ããã¯é£éŠæ³ã§ "äžå¯é¿çã«å®å šã§ãªã "ãšã¿ãªãããŠããã
ãããåŸãå®å šã§ãªãããããã®è£œé æ¥è ã¯é£éŠæ³ã«ãã£ãŠãåžæ°ã«å±å®³ãäžããå Žåã®è²¬ä»»ããä¿è·ãããŠããã
ããã«ãããããããã¡ãŒã«ãŒãæ¿åºæ©é¢ã¯ã"ãããåŸãå®å šã§ãªã "ãšããæ³çå°äœãšã¯æ£å察ã«ã"å®å šã§å¹æçã§ãã "ãšå ¬ã«å®£äŒããŠããã
ãã®æ°ã¯ããæ°å幎ã§é©ç°çã«å¢å ããŠãããmRNAæè¡ãšãã¯ã¯ãã³ããšããèšèã®å®çŸ©ã®æ¡å€§ã«ãããå°æ¥çã«ã¯ããã«å¢å ããããšãäºæ³ãããã
ãã®10ã®æç« ããçŽåŸããŠããªã人ã ããã¯ã¯ãã³ãåãå·»ãäžå¿çãªãã°ããåèããå©ãã«ãªãããšãé¡ã£ãŠãããç§ãã¡ã¯ã瀟äŒãšããŠãã¯ã¯ãã³ãåºæ¬çã« "å®å šã§å¹æç "ã§ãããšããä¿¡ä»°ãåŠå®ããå¿ èŠãããã
ã¯ã¯ãã³ã¯ããã®äžå¯é¿çã«å®å šã§ãªããšããæ§è³ªãããæ±ºããŠçŸ©ååãããã¹ãã§ã¯ãªããåã ã®ã¯ã¯ãã³ã«ã€ããŠè£œåããšã«åŸ¹åºçãªäŒèšåŠçãæ¿åºæ©é¢ä»¥å€ã§è¡ãå¿ èŠãããã
ã©ãããã°ãããéæã§ããã®ã ãããïŒ
ããååã ãšæããããããããªããããèš±ãããã ããããã¯ã¯ãã³ã®åé¡ã«å¯Ÿããç§ã®è§£æ±ºçæ¡ãåæãããšãããš10æããã
ãããã«ãç®ãéããŠããã ããããã»ãšãã©ã®æç« ã¯æåã®10æããçããããããšãããããŸããã
ã¯ã¯ãã³ã®åé¡ã«å¯Ÿãã解決çã10æïŒä»¥äžïŒã§ææ¡ïŒ
NCVIAã廿¢ããã¯ã¯ãã³ãä»ã®å»è¬åãšåãè²¬ä»»ç¶æ ã«æ»ãã¹ãã§ããã
ããããã¬ãã«ã®æ¿åºã«ãããŠãããããã¯ã¯ãã³ã®æ¥çš®ã矩åä»ããããšãçŠæ¢ããé£éŠæ³ãå¶å®ãã¹ãã§ããã
åŠæ¹è¬ã®æ¶è²»è ãžã®çŽæ¥åºåããã¹ãŠçŠæ¢ããé£éŠæ³ãå¶å®ãã¹ãã§ããã
HHSã®ãã¢ã«ãã¡ãããã¹ãŒããæ©é¢ïŒFDAãCDCãNIHãªã©ïŒãšç±³åœé²ç·çïŒç±³éžè»ãåœé²é«çç ç©¶èšç»å±ãªã©ïŒãŸãã¯é£éŠæ å ±æ©é¢ïŒCIAãç±³åœåå®å šä¿éçãªã©ïŒãšã®éã®ã¯ã¯ãã³éçºãŸãã¯äžè¬åžæ°ãžã®ã¯ã¯ãã³é åžã«é¢ãããã¹ãŠã®ååãçŠæ¢ããé£éŠæ³ãå¶å®ãã¹ãã§ããã
5.HHSæ©é¢å ã§åããã¹ãŠã®è ããç¹èš±ããã€ã€ãªãã£ã®ååŸã»ä¿æãå«ããã¯ã¯ãã³ããå人çãªééçå©çãåŸãããšãçŠæ¢ããé£éŠæ³ãå¶å®ãã¹ãã§ããããããŠããããã®æ©é¢ã®å ¬åå¡ã¯ãæ¿èªããèŠå¶ãããããã¯åœæ°ã«å©èšãããããªã補åãããå©çãåŸãªããšå®£èªããããšã矩åä»ããããã¹ãã§ããã
COVID-19 mRNAã¯ã¯ãã³ã®éçºãããŒã±ãã£ã³ã°ã補é ã販売ãæäžã«é¢äžããäž»èŠãªé¢ä¿è ïŒå®æ°åæ¹ïŒã«ã€ããŠãé©åãªå Žåã«ã¯åäºèšŽè¿œãå«ã培åºçãã€å ¬çãªèª¿æ»ãè¡ãã調æ»åŸãHHSæ©é¢å ã§é©åãªæ¹é©ãè¡ãã¹ãã§ããã
CDCã®ã¯ã¯ãã³ã¹ã±ãžã¥ãŒã«ã«ãããã¹ãŠã®ã¯ã¯ãã³ã«ã€ããŠã詳现ã§ç¬ç«ããã³ã¯ã©ã³ã»ã¹ã¿ã€ã«ã®ã¬ãã¥ãŒã宿œããå ¬è¡šãã¹ãã§ããã
COVID-19 mRNAã¯ã¯ãã³ã«é¢é£ããVAERSããã®ãã¹ãŠã®å ±åã«ã€ããŠã詳现ã§ç¬ç«ããã¬ãã¥ãŒã宿œããå ¬è¡šãã¹ãã§ãããVAERSã«å¯ŸããŠé©åãªæ¹é©ãè¡ãã¹ãã§ããã
ã¯ãŒãã»ã¹ããŒãäœæŠãã³ãããŠã€ã«ã¹æ¯æŽã»ææžã»çµæžå®å šä¿éæ³ïŒCARESæ³ïŒãå«ãCOVID-19æä»£ã®ããã°ã©ã ã«é¢é£ããè³éçµè·¯ã®è©³çްãªè°äŒã¬ãã¥ãŒã宿œãããã¡ã€ã¶ãŒãã¢ããã®ãããªæ°éäŒæ¥ããçŽçšè ãè³éãæäŸããã€ãã·ã¢ããããããã«è«å€§ãªå©çãåŸãããå«ããããããã¬ãã«ã§ã®äžæ£ãšä¹±çšã«çŠç¹ãåœãŠãã¹ãã§ããã
å ¬è¡è¡çã«ãããã¯ã¯ãã³ã®é©åãªåœ¹å²ã«ã€ããŠããšãããä»ã®åé¡ãå«ããå ¬éã®èšè«ãšèšè°ãè¡ãããšïŒ
ã¯ã¯ãã³ã«é¢ããçŸåšã®å»åŠçãã°ããæ¹å€çã«èŠçŽãã
COVID-19æä»£ã®éã¡ãæ¿«çšãæœåšçæèšã®èª¬æã
çŸåšå®è·µãããŠããå ¬è¡è¡çãšåžæ°ã®åºæ¬çåžæ°æš©ãšã®éã®åŠå®ã§ããªãççŸã«ã€ããŠã®åŸ¹åºçãªè°è«ã
ã¯ã¯ãã³ã«é¢ããå»åŠçã®çŸåšã®ãã°ãïŒãå®å šã§å¹æçããåçç¡çšïŒãšãããã«å¯Ÿå¿ããã«ãããºã ïŒæ¡å€§ãç¶ããã¯ã¯ãã³ã¹ã±ãžã¥ãŒã«ïŒã¯ãçµ¶æçã«æ¹é©ãå¿ èŠã§ãããç§ã¯ãäžèšã®ã¹ãããããå§ããããšãææ¡ããã
æ¹é©è ãã¡ã¯ç°ç«¯è ã§ã¯ãªãããæ¹é©ã«æµæããæš©åè ãã¡ããã¯ãã®ãããªã¬ããã«ã貌ãããã®ãåžžã§ããã
ç§ã¯ç°ç«¯è ã§ã¯ãªããã"åã¯ã¯ãã³è«è "ã§ããªãã
èµ€ãåã颚åã®æ°Žãšäžç·ã«æšãŠããã¯ãªããåé¡ãªã®ã¯ãã¯ã¯ãã³ã®ã¹ã±ãžã¥ãŒã«ãããèŠããšã宣äŒãããŠããããããã£ãšå€ãã®é¢šåã®æ°Žããããèµ€ã¡ãããå°ãªããšããããšã ã
å»åŠã®å°éå®¶ãšç€ŸäŒå šäœãããã®ããŒãã«ã€ããŠæé»æä»£ããæãåºãæã§ããã
ã¯ã¯ãã³ãšå ¬è¡è¡çã«ããããã®åœ¹å²ã«ã€ããŠããªãŒãã³ã§ççŽãªåè©äŸ¡ãè¡ãæãªã®ã§ããã
åæïŒBrownstone Institute
ã¯ã¬ã€ãã³ã»Jã»ãã€ã«ãŒå»åŠå士ã¯ãååäžçŽã«ããã£ãŠèšåºã«æºãã£ãŠããå ç§å»ã§ããããããŸã§ã«æ°å€ãã®åŠè¡çãªåœ¹è·ãæŽä»»ããJournal of the American Medical AssociationãNew England Journal of Medicineãªã©å€ãã®ãžã£ãŒãã«ã«è«æãæ²èŒãããŠããã2012幎ãã2018幎ãŸã§ããã§ã¹ã¿ãŒå€§åŠå»ç人æã»çåœå«çã®èšåºåææã
æ¬èšäºã§è¿°ã¹ãããŠããèŠè§£ãæèŠã¯èè ã®ãã®ã§ãããå¿ ãããChildren's Health Defenseã®èŠè§£ãåæ ãããã®ã§ã¯ãããŸããã